Abstract The insulin-like growth factor type 1 receptor (IGF1R) is involved in progression of breast cancer and resistance to systemic treatment. Targeting IGF1R signaling may, therefore, be beneficial in systemic treatment. We report the effect of IGF1R expression on prognosis in invasive ductal breast carcinoma (IDC), the most common type of breast cancer. Immunohistochemistry was performed on tumor tissue of a consecutive cohort of 429 female patients treated for operable primary IDC. Associations between IGF1R expression with clinicopathological parameters, disease free survival (DFS) and breast cancer specific survival (BCSS) were evaluated by multivariate analyses focusing on ER-positive and triple negative IDC (TN-IDC). To enlarge the TN-IDCs cohort, we analyzed a 
Introduction
Signaling via the insulin-like growth factor type 1 receptor (IGF1R) plays a crucial role in proliferation, cell survival, invasion, and metastatic behavior of many cancers, including breast cancer [1, 2] . In addition, IGF1R is implicated in resistance to chemotherapy, hormonal therapy, Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) directed therapies [3] [4] [5] .
IGF1R is a transmembrane tyrosine kinase receptor activated by binding of IGF-1 or -2 [6] . Subsequently, signaling occurs via Src homology 2 domain-containing protein, insulin receptor substrates, phosphatidylinositol-3-kinase/Akt, and mitogen-activated protein kinase pathways [7] [8] [9] . High IGF1R expression levels have been reported in a wide range of human malignancies, but correlations with tumor characteristics and outcome are infrequently found [10] . Based on in vitro and in vivo data with IGF1R antibodies and tyrosine kinase inhibitors, responses are expected in a variety of carcinomas [3, [11] [12] [13] [14] . IGF1R targeted therapy in breast cancer is particularly interesting, because synergy with anti-hormonal therapy and targeting of related receptor tyrosine kinases HER2 and EGFR has been shown [15] [16] [17] . There is evidence coming from cell line studies suggesting IGF1R-signaling has different effects on cellular characteristics like proliferation and migration in ER-negative tumors as opposed to ER-positive tumors [18] [19] [20] . However, it is still unclear which factors contribute to sensitivity to anti-IGF1R directed therapy as no biomarker is available yet to select patients and tumor types.
Breast cancer is a heterogeneous disease with different sensitivity to drug treatment and outcome between different histological and molecular subtypes [21, 22] . Previous studies showed high IGF1R expression in human breast carcinomas, [23] [24] [25] [26] [27] and several studies showed correlations of IGF1R expression with estrogen receptor expression and well-differentiated carcinomas [23, 27, 28] . A special subgroup of breast carcinomas, called triple negatives (TNs), defined by absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, has a worse prognosis and lacks a scaffold for conventional targeted treatments [29] . Identification of new targets in TNs are warranted to extend the armamentarium for this relatively poor prognostic subgroup of breast cancer. The IGF1R could be a target and thereby providing new treatment options.
In the current study, IGF1R expression was investigated in a consecutive cohort of patients with invasive ductal carcinomas (IDCs) of the breast. In this way, the value of IGF1R expression in the most prevalent histological subtype can be related to patient and tumor characteristics, molecular markers, and prognosis. For above-mentioned reasons special attention will be put on TN-IDCs. For the latter, we combined two datasets of TN-IDCs with similar clinicopathological parameters.
Patients, materials, and methods

Patients
A consecutive cohort of 429 female patients treated for a primary local or locally advanced invasive ductal breast carcinoma, as defined by the WHO classification [30] at the University Medical Center Groningen between January 1996 and December 2005 was included in this study. In this same period 26 patients presented with a synchronous (n = 4) or metachronous (n = 18) contralateral breast tumor or a recidive tumor (n = 4), these patients were not included in our cohort.
All patients received local treatment, i.e., breast conserving therapy including radiotherapy or ablative surgery, both with lymph node staging (sentinel node procedure and/or axillary dissection). Local therapy was followed by chemotherapy in 118 patients (96/118 anthracycline-containing chemotherapy (AC/FEC/CAF); 20/118 cyclophosphamide, methotrexate, and fluorouracil (CMF); 2/118 taxane based). In 55 patients chemotherapy was combined with endocrine treatment, 97 other patients received only endocrine systemic treatment (total n = 152; 121/146 tamoxifen; 24/146 aromatase inhibitor; in 7 patients who remained premenopausal after received chemotherapy, a LHRH analogue was added). Only 4 patients received herceptin. Patient and tumor characteristics and data on follow-up were obtained from hospital records ( Table 1) . The medical ethical committee of the University Medical Center Groningen approved this study.
To study a subgroup of patients in more detail, 51 triple negative breast carcinomas (TN-IDCs) from the cohort described above (Groningen dataset) were combined with a previously described cohort of 71 TN tumors (Amsterdam dataset) [31] , from which 64 were invasive ductal carcinomas and evaluable for IGF1R expression in our study. The two populations were similar with regard to patient and tumor characteristics, local and systemic therapy and survival (Supplementary Table 1 ).
Characterization of breast carcinomas by immunohistochemistry
A tissue microarray was constructed as previously described [32, 33] . TMA sections were stained with antibodies against IGF1R, insulin receptor (IR), phosphorylated-Akt (p-Akt), ER, PR, and HER2. Specific details of the antibodies and their antigen retrieval methods used are summarized in Supplementary Table 2 . The immunohistochemical methods in general were previously described by van der Vegt et al. [34] for ER, PR, and HER2 staining. Fig. 1 . To confirm the robustness of the staining pattern for IGF1R using the 24-31 antibody, a tissue microarray of 50 consecutive invasive breast carcinomas was stained using the same clone provided by another supplier (clone 24-31, Neomarkers, Fremont CA, USA; dilution 1/800). Each individual core of both stained tissue microarrays can be seen at http://telepathology.nki.nl (Login: igf1r, Password: nkiavl). For all stainings, the highest score out of three cores from the same tumor was used for the analysis. If one or two cores out of three failed, the highest value of the remaining core(s) was included in the analysis. Only the invasive tumor component was considered when judging the staining. When no (invasive) tumor cells were available in the sample, the result was considered 'missing' in the statistical analysis.
Statistical analysis
Since the clinical relevance of IGF1R localization is yet unknown, separate analyses were conducted for 1. positive cytoplasmic IGF1R staining vs. no cytoplasmic staining, 2. positive membranous vs. no membranous staining and 3. any positive staining (cytoplasmic, membranous, or both) vs. negative staining pattern (further addressed as ''overall IGF1R expression'').
Univariate and multiple logistic regression analyses were performed to evaluate the associations of IGF1R expression with clinical (age, menopausal status, lymph node status, surgical, and adjuvant therapy), tumor (size and differentiation grade), and immunohistochemical (ER, PR, IR, HER2, and p-Akt) characteristics. Multivariate Cox regression analysis was used to explore the relationship between IGF1R and the following survival endpoints; (1) disease free survival (DFS), defined as time to any recurrence (local or regional or distant), and (2) breast cancer specific survival (BCSS). Clinicopathological variables that had a significant univariate association (Tables 2,  3) were entered simultaneously in a multivariate Cox regression model. Log-rank tests were performed to evaluate the difference in group-specific survival which is illustrated by Kaplan-Meier plots. All statistical analyses were performed using the statistical package SPSS 16.0 (SPSS inc., Chicago, IL, USA).
Findings
Immunohistochemistry
Immunohistochemistry for IGF1R could be evaluated in 368 cases (86%). In case IGF1R was present, the intensity of the staining was strong and uniformly present in all tumor cells in 295 cases (80%). Pure membranous IGF1R expression was present in 8%, pure cytoplasmic in 21%, Fig. 1 a- Prognostic relevance of IGF1R staining pattern Cytoplasmic, but not membranous or overall IGF1R expression was strongly associated with prolonged DFS (HR 0.46, 95% CI 0.27-0.49, P = 0.005) and increased BCSS (HR 0.38, 95% CI 0.19-0.74, P = 0.005) (Figure 2 ).
Tumor size, differentiation grade, and PR were multivariately significant factors for DFS (Table 4) . Interestingly, while in ER-positive tumors cytoplasmic IGF1R expression is a favorable prognostic factor, in ER-negative tumors this effect is lost and membranous staining is related to a worse prognosis (DFS) (log-rank P = 0.02) (Fig. 3) .
Subsequently, significant univariate parameters for BCSS (Table 3) were analyzed by multivariate Cox regression in which differentiation grade and HER2 were prognostic factors (Supplementary Table 5 ).
Effect of IGF1R expression in triple negative breast carcinomas
This interesting result, i.e., a possible opposite effect of IGF1R expression on prognosis of ER-positive versus Table 1 ). For the Amsterdam cohort, the majority of patients was treated by breast conserving therapy (BCT) including post-operative radiotherapy, whereas for the Groningen dataset approximately halve of the patients were treated by BCT. Immunohistochemistry for IGF1R could be evaluated in 105 triple negative cases (91%). IGF1R was expressed in 52 cases (45%). Pure cytoplasmic IGF1R expression was present in 11 cases (10%) and pure membranous IGF1R expression in 11 cases (10%). In total, 30 cases (26%) had combined membranous and cytoplasmic staining. We found no association between membranous or cytoplasmic IGF1R expression and clinicopathological parameters.
In the combined patient cohort of 105 TN-IDCs, cytoplasmic IGF1R expression has an unfavorable prognostic impact on DFS (cytoplasmic: HR = 2.29, 95% CI 1.08-4.84, P = 0.03; membranous: HR 1.98; 95% CI 0.94-4.17, P = 0.07). Comparable direction and magnitude of effects were seen in both triple negative databases separately (cytoplasmic HR 2.99 and 1.83 resp.; membranous HR 1.58 and 1.83 resp.), although not consistently statistically significant, most likely due to lower numbers in the separate databases, and thus reduced power. In a multivariate analysis, including all well-known prognostic clinicopathological parameters, cytoplasmic IGF1R expression was a near-significant prognostic factor for DFS (HR 2.06; 95% CI 0.95-4.47; P = 0.07) ( Table 5 ).These same associations were also found when only time to distant metastasis A B 
Discussion
In this study, we found that cytoplasmic expression of IGF1R in ER-positive invasive ductal breast carcinomas is associated to a more favorable prognosis, while in triple negative breast carcinomas IGF1R expression is associated to a poor outcome. This study underlines that the clinical impact of transmembrane tyrosine kinase receptor expression should be interpreted in the context of the carcinoma subtype, such as co-expression with hormone receptors. We found IGF1R expression in 80% in our series of invasive ductal breast carcinomas (IDC). The majority of these tumors (62%) had combined cytoplasmic and membranous staining. Since the clinical relevance of IGF1R localization is yet unknown and our goal of the present study was evaluation of a candidate prognostic biomarker that would be clinical applicable, separate analyses were conducted for cytoplasmic, membranous, and overall staining. Cytoplasmic IGF1R staining highly correlated with hormone receptor expression, well differentiated breast carcinomas, and to a more favorable prognosis. This prognostic effect occurred specifically in ER-positive breast carcinomas. Since cytoplasmic staining patterns of tumor samples incorporated on the same TMA-slide show differential staining intensity and subsequent significant correlation with biologic plausible factors, we considered this not an artifact but a relevant observation which should not a priori be ignored. Moreover, the robustness of IGF1R staining intensity and staining pattern was confirmed using an antibody of the same clone provided by another supplier on a tissue microarray of 50 randomly chosen invasive breast carcinomas.
Although the biologic significance of cytoplasmic localization of the IGF1R has received little attention in the literature up till now, cytoplasmic localization has been observed before. Confocal microscopy images studying subcellular localization of IGF1R show cytoplasmic staining [35, 36] . Some have reported cytoplasmic IGF1R staining by IHC [37, 38] , while others have chosen to ignore cytoplasmic staining, although endoplasmatic staining had been present [39] . Biologically cytoplasmic IGF1R has been linked to mutant receptors which show abolished cell surface expression and endoplasmatic retention of the receptor due to failure to traffic to the cell membrane [40] . Also, accumulation of IGF1R into the cytoplasm has been observed after internalization and intracellular trafficking induced by binding of ligand or antibodies, resulting in receptor degradation [36] . Most of the biologic effects of the IGF1R have been ascribed to its tyrosine kinase activity, which propagates signaling through the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Recently, however, IGF1R translocation to the nucleus has been described and shown to activate transcription but not alter its kinase-dependent signaling [41, 42] . This is analogue to the earlier observation that ErbB family proteins are expressed in the nucleus and can function as transcriptional regulators [43] . Although cytoplasmic or nuclear HER2 staining by IHC in clinical tumor samples is not considered to be relevant for prognosis or selection of HER2 targeted therapy, the biological relevance of nucleocytoplasmic trafficking has been accepted.
In our samples, nuclear IGF1R expression did not become evident. Of particular interest is the relation of IGF1R localization with ER expression. Interaction of IGF1R and ER has been shown in numerous studies, but this interaction also involves physical co-localization. Reported co-localization of the ER, which is generally localized in the nucleus, with IGF1R at the cell membrane underscores the diversity of receptor localization [35] . Taken together, these data suggest that protein localization of tyrosine kinase receptors is a highly dynamic biological process. The specific details of functional implications of IGF1R cytoplasmic localization need to be appreciated in future studies.
In previous studies, similar associations of ER and IGF1R expression were reported [27, 28, 44] , e.g., Ueda et al. [27] described a favorable prognosis for IGF1R expression in ER-positive carcinomas. In triple negative breast carcinomas (TN-IDCs) we found IGF1R expression in 65% of the cases. In these tumors cytoplasmic staining showed some relation to shorter DFS, although no effect was found on overall survival rates. In line with our results, Railo et al. [45] reported similar worse survival rates in ER-negative IGF1R expressing breast carcinomas.
Our observation of a different association between IGF1R expression and prognosis in ER-positive versus ER-negative carcinomas is supported by in vitro studies. In breast cancer cell lines IGF1R and ER synergistically stimulate proliferation [20] , but in the absence of ER, IGF1R activation fails to induce mitogenesis, while its migratory actions are retained [18, 19] .
High circulating IGF1 levels are by now a well-established risk factor in women for developing breast cancer [46, 47] , and a most recent collaborative analysis of 17 prospective studies established that the risk-association is confined to ER-positive tumors [48] . These data strongly support a notion of altered biologic and prognostic significance of IGF1 and IGF1R in ER-positive vs. ER-negative tumors as presented in our study.
Most likely, IGF1R expressing, ER-positive carcinomas represent a large subclass of breast carcinomas with presumably a distinct biology and an excellent prognosis. It could be hypothesized that well-differentiated, ER-positive breast cancers retain physiological growth control by ER A B Fig. 3 Kaplan-Meier plots of group-specific associations of IGF1R expression with disease free survival in ER-positive (a) and ER-negative (b) breast carcinomas and IGF1R signaling, while in ER-negative carcinomas IGF1R expression confers primarily metastatic capacities. Hormone receptor positive invasive ductal breast cancers are nowadays treated with adjuvant tamoxifen and/or aromatase inhibitors during 5 years or longer. Long-term survival benefit of hormonal therapy is reported to be 4-12% [21] . Because IGF1R and hormone receptors closely interact, a combination of hormonal therapy with IGF1R drugs may help to block all mitogenic hormonal responses. Also, as modulations of the IGF1R system have been implicated in development of resistance to endocrine therapies, IGF1R directed therapy may overcome or prevent development of hormone therapy resistance [4, 49, 50] . Indeed, synergistic effects of IGF1R targeting drugs with hormonal therapies have been reported in vivo [3] . Therefore, we suppose that IGF1R directed therapy may complement therapy for hormone receptor positive breast cancers, in particular in case of constitutive or acquired resistance to endocrine therapy.
Our patient cohort covers a considerable time span, in which the indications and therapeutic options for surgical and systemic treatment have further been developed and adjusted. Surgical treatment (mastectomy vs. lumpectomy followed by radiation), received chemotherapy, and hormonal therapy were included in our multivariate survival models and group by group analysis was conducted for anthracycline-containing chemotherapy versus no chemotherapy and for tamoxifen versus no hormonal treatment (data not shown). Herein we found no evidence that the survival benefit of IGF1R expression on prognosis in our study was compounded by interaction with adjuvant systemic therapy. However, changing chemotherapy regimens, different hormonal treatment and shifting indications for adjuvant treatment over this period of time could not entirely be accounted for in our models.
In the Amsterdam dataset of TN-IDC more patients were treated with breast conserving surgery followed by radiation than in our cohort. Breast conserving surgical therapy bears a slightly increased risk on local recurrence of the tumor. However, our finding of an unfavorable prognostic impact of IGF1R on DFS in this population held true when time to distant metastasis was tested and was not attributed to local recurrences.
The present database was considered less appropriate for studying effects on prognosis in HER2 positive tumors, because herceptin had not yet been introduced as a standard adjuvant systemic treatment in this patient group during the inclusion period of this study. Also, correlations with HER2 may be inaccurate, since only 3? HER2 cases were considered positive, and 2? cases were not subjected to FISH analysis. Activation of PI3K signaling, which among multiple other signals is induced by IGF1R, occurs often in breast carcinomas [51] and has been related to limited sensitivity to HER2 directed therapy [52] . We, however, found no correlation of IGF1R expression with staining of phosphorylated-Akt or PTEN, neither with RNA expression of PI3K pathway related genes (data not shown). Therefore, we could not show PI3K to be a dominant pathway emerging from high IGF1R expression and we can only speculate on the functional significance of positive IGF1R expression. Since an IGF-1 signature has been published predicting worse prognosis of ER-positive breast carcinomas [53] it is of interest to test whether the presence of such a signature is related to IGF1R expression on the protein level.
As the IGF1R is highly homologous to the IR, and they share several functions [1] , IR expression was studied but no relation with clinicopathological parameters or IGF1R expression pattern could be shown. Although there are data suggesting IR is also a favorable prognostic factor [54, 55] we could not reproduce these results. Among other explanations, using antibodies with different specificity for (splice variants) of IR and IGF1R-IR hybrids may have played a role.
Interestingly, Law et al. [56] reported that phosphorylated IGF1R and insulin receptor (IR) can be found in all breast carcinoma subtypes and is related to a poor survival. Whether detection of phosphorylated IGF1R and IR outperforms the detection of IGF1R expression as presented here as a biomarker is subject of ongoing studies.
In TN-IDCs, inhibition of the IGF1R-mediated signaling is likely to have a clear beneficial effect as has been shown for a mouse model carrying basal type breast carcinomas [57] . Within this perspective, clinical phase trials of IGF1R antibodies and tyrosine kinase inhibitors or antibodies blocking the IGF1R signaling should focus both on ERpositive as well as TN-IDCs. With regard to the importance of cytoplasmic IGF1R expression, treatment with tyrosine kinase inhibitors may be advantageous over antibodies. The clinical development of antibodies against the IGF1R membrane receptor, however, is far ahead of the tyrosine kinase inhibitors, which is also understandable with regard to the expected side effects of such a treatment.
In conclusion, IGF1R expression in invasive ductal breast carcinomas is a strong favorable prognostic factor in ER-positive, but highly likely an unfavorable factor in TNIDCs. The findings of our study combined with those of others strongly suggest that targeting IGF1R signaling is likely to be a promising treatment strategy of IGF1R expressing breast carcinomas. Clearly, further validation studies according to well established criteria are required to implement the IGF1R as a biomarker that could assist making a rational choice for IGF1R targeted therapy [58] .
